Confirm mdx
PCR-based DNA methylation test performed on prior negative prostate-biopsy tissue to estimate the likelihood of occult clinically significant prostate cancer and inform repeat-biopsy decisions.
- Developer
- mdxhealth
- Intended use
- Diagnostic Aid
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA methylation
- Current version
- Confirm mdx current prostate biopsy methylation configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.